Another study showed that PD-L1 positivity in the tumor led to a better ORR of 58.8% in PSCs treated with second-line or beyond immunotherapy than PD-L1 negativity, and the median OS was 12.7 months in the whole sample. Here, CD274 is linked to neoplasm.